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OBJECTIVES: End-stage renal disease (ESRD) poses a high medical and economic
burden on healthcare systems. Information on direct medical costs for dialysis
patients in Mexico is comparatively sparse. METHODS: Data was collected retro-
spectively on 40 patients on automated peritoneal dialysis (APD) and 40 patients on
hemodialysis (HD) from institutional databases of two hospitals of the Mexican
Institute of Social Security (IMSS). Patient follow up ranged from 3 months up to 67
months. Resources captured in the study were: medications, dialysis procedures,
laboratory and diagnostic tests, hospitalizations and medical consultations, blood
and hemoderivatives and catheter procedures. Drug and medical services costs
were calculated using information from the Mexican Government website (http://
web.compranet.gob.mx ) based on 2010 fees. All costs were converted into US
dollars (1USD  12.54 Mexican pesos ). RESULTS: Forty patients on peritoneal di-
alysis (APD, age 50  15.6, 40% female) and 40 patients on hemodialysis ( HD , age
47  17.3 years , 42,5 % female). Total annual costs were: USD 12,589 (APD), USD
7,541 (PD). Dialysis: USD 1,058 (APD) , USD 13,739 (HD). Hospitalization: USD 6,212
(APD), USD 6,128 (HD). Medication: USD 5,043 ( APD), USD 7,580 (HD). Costs for
complications: USD 5,586 (APD) and USD 3,943 (HD). CONCLUSIONS: Dialysis pa-
tients either on peritoneal or hemodialysis present a high cost burden to the Mex-
ican Health system. Medication and hospitalization costs constitute a major part of
the total costs. Further investigations are needed to understand how to optimize
care to avoid some of these costs.
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OBJECTIVES: Secondary Hyperparathyroidism (SHPT) is a common complication of
chronic kidney disease. Abnormal levels of Parathyroid Hormone (PTH), Calcium
(Ca) and Phosphorus (P) are associated with an increased risk of cardiovascular
death and fracture. The aim of the study was to assess the cost per successful
response with standard treatment (ST)Cinacalcet versus ST alone (vitamin D
sterols and chelated phosphates) in patients with SHPT in Mexico. METHODS: A
decision analytic model was developed to calculate and compare the costs per
successful response with Cinacalcet in adult patients with SHPT to whom a specific
scheme of ST has been prescribed. The successful response was defined as the
balance (normal levels) in all target parameters: PTH, Ca, P and Ca x P. ST was
defined as one of the following combinations: Paricalcitol IV Chelated Phosphate
(PCP), Chelated Phosphate  Calcitriol (CPC) and Paricalcitol  Calcium Carbonate
(PCC). Unit costs were gathered from the 2010 Official Price List of the Public Health-
care System in Mexico. RESULTS: According to the literature, 16% of patients
achieve the targets in all parameters when ST is given. The addition of Cinacalcet
increases this proportion up to 60%. Considering PCP as the ST, the cost per re-
sponse was MXP$32,750 vs MXP$16,945 with CinacalcetPCP; CPC showed a cost
per response of MXP$22,156 vs MXP$15,509 with CinacalcetCPC; finally, PCC re-
flected a cost per response of MXP$14,850 vs. MXP$12,091 with CinacalcetPCC.
CONCLUSIONS: The addition of Cinacalcet to any ST combination represents a
strategy which results to lower cost per responder principally due to two factors:
the reduction of 50% in ST concomitant drugs and the higher response rates in
achieving targets for all biochemical parameters.
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OBJECTIVES: This study sought to determine the cost-effectiveness of anemia
treatment in dialysis patients for Brazilian Public Health System. Two alternatives
were compared: a new drug, the Continuous Erythropoietin Receptor Activator, CERA,
recently registred in Brazil, and another one, provided nowadays by the National
Health System, Epo-rHu (Recombinant Human Eythropoietin). METHODS: A
Markov cohort of dialysis patients treated with CERA and Epo-rHu for four years
was used to perform the base case analysis. The model outputs were QALYs and
costs. The quality of life associated with each drug was measured by interviews
applied to health care professionals. These interviews were previously submitted
and approved by the local ethics committee. A sensitivity analysis was applied to
the model to test it, varying the values of drugs dosage, costs, discount rate and
effectiveness. RESULTS: The average quality of life assigned by health care profes-
sionals to the patients treated with Epo-rHu, CERA and to kidney transplant recep-
tors were respectively 6,3, 7,8 and 9,3. The model showed that Epo-rHu treatment
was more cost-effective than CERA treatment. The cost-effectiveness ratio of Epo-
rHu therapy was R$ 21.052,00. In addition, the cost per QALY gained of CERA ther-
apy was R$ 72.974,00. CONCLUSIONS: Anemia treatment with CERA is associated
with improvement in quality of life compared to Epo-rHu therapy. However, the
new drug is not more cost-effective than the drug provided by the Brazilian Public
Health System.
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OBJECTIVOS: Análisis de costo-efectividad en intervenciones para pacientes con
insuficiencia renal crónica terminal (IRCT) en términos de los costos económicos de
cada intervención, los años de vida ganados y la calidad de vida que generan tres
alternativas comparables y mutualmente excluyentes: diálisis peritoneal continua
ambulatoria (DPCA), la hemodiálisis (HD) y el trasplante renal (TR).
METODOLOGÍAS: El diseño del estudio fue de tipo longitudinal. Los costos de cada
intervención se determinaron mediante la técnica de manejo de caso promedio.
Las medidas para evaluar los criterios de efectividad elegidos fueron la probabili-
dad de sobrevida y el Año de Vida Ajustado por Calidad (QALY, Quality-Adjusted
Life Year) medido por el Indice de Rosser. RESULTADOS: Los costos de manejo
anual de caso en US $ fueron: diálisis peritoneal $470.00, hemodiálisis $802.00 y
trasplante $231,00. En cuanto a la efectividad, la sobrevida del injerto de trasplante
renal resultó de 89,9% y 79,6% a uno y tres años respectivamente, mientras que los
pacientes sometidos a DPCA tienen una sobrevida de 86,2% y 66,9% a un año y a tres
años respectivamente. En cuanto a los QUALY’s, los resultados para cada interven-
ción fueron: DPCA 0,879; HD 0,864; y para el TR 0,978. CONCLUSIONES: La interven-
ción más costo-efectiva resultó el trasplante renal con un coeficiente de 3088,69,
seguido de la DPCA y la hemodiálisis, cuyos coeficientes fueron de 6416.95 y
11.147,68 respectivamente. Por lo tanto se recomienda promover y utilizar el tras-
plante renal como la intervención más costo-efectiva para pacientes con IRCT. Los
resultados del coeficiente costo-efectividad identificado desde una perspectiva
clínica y económica, constituyen un aporte relevante para la búsqueda y el logro de
la eficiencia de los recursos que se asignan para producir servicios de salud para
pacientes con IRCT, cuyas demandas están en competencia con otras enfer-
medades crónicas e infecto-contagiosas.
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OBJECTIVOS: Evaluar si el uso de Metoxi polietilenglicol-eritropoyetina beta (MPG-
beta) ofrece mejores resultados en salud y gasto con respecto a la eritropoyetina
alfa. METODOLOGÍAS: Análisis de costo-efectividad incremental basado en un ár-
bol de decisiones para simular los costos del tratamiento, con un horizonte tem-
poral de 12 meses (costos en valor nominal). La dosis mensual de agentes estimu-
lantes de la eritropoyesis se ajustó de acuerdo con los niveles de hemoglobina; sí la
concentración es mayor a 12 g/dl 20,000 UI/mes de Eritropoyetina alfa o 0.6 mcg/
kg/mes de MPG-beta, para 11-12 g/dl 26,00 0UI/mes de Eritropoyetina alfa o 1.2
mcg/kg/mes de MPG-beta y para concentraciones menores a 11 g/dl 32,000 UI/mes
de Eritropoyetina alfa o 1.5 mcg/kg/mes de MPG-beta. Cada escenario tiene un costo
basado en la atención habitual de estos pacientes. Los costos de los insumos se
tomaron de las tarifas vigentes para 2010 aplicables a los servicios médicos pro-
porcionados por el IMSS. Se evaluaron los riesgos de no estar en un intervalo ideal
de Hemoglobina (11-12.5 g/dl), también conocido como excursiones de la hemoglo-
bina y su costo asociado. RESULTADOS: MPG-beta mantiene en forma más estable
la concentración de hemoglobina al compararse con Eritropoyetina alfa, de tal
forma que a los 6 meses de tratamiento permanecen en el intervalo ideal 94% vs. 5%
con Eritropoyetina alfa. Con el uso de Eritropoyetina alfa hay mayor riesgo de tener
excursiones, y por consecuencia se incurre en mayores costos anuales (67,612 vs.
63,931). El análisis costo-efectividad incremental muestra un incremento de 83% en
efectividad y un ahorro por paciente de 3,681 utilizando MPG-beta en comparación
con Eritropoyetina alfa, esto derivado de la estabilidad de la hemoglobina. El ICER
es de -12,901 unidades. CONCLUSIONES: Estos resultados demuestran que MPG-
beta ofrece mejores resultados en salud y costos posesionándose como un trata-
miento costo-ahorrador.
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